Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
50mg |
|
||
Other Sizes |
|
Purity: ≥98%
Xevinapant HCl (formerly Debio-1143 HCl; AT406; SM406, ARRY334543 HCl) is a potentially first-in-class and oral antagonist of IAP (inhibitor of apoptosis protein via E3 ubiquitin ligase) proteins, also a peptidomimetic of SMAC (second mitochondrial-derived activator of caspases)/DIABLO with potential antitumor activity. It acts by binding to XIAP-BIR3, cIAP1-BIR3 and cIAP2-BIR3 with Kis of 66.4 nM, 1.9 nM, and 5.1 nM, respectively.
ln Vitro |
Cell growth of the breast cancer MDA-MB-231 and the ovarian cancer SK-OV-3 cell lines is effectively inhibited by xevinanapant (AT-406) hydrochloride, with IC50 values of 144 nM and 142 nM, respectively. Potently inducing cell death in a time- and dose-dependent manner is xevinanapant hydrochloride (0-3 μM; 0-48 hours) [1].
|
---|---|
ln Vivo |
Xevinanapant (AT-406) hydrochloride is highly efficient in suppressing tumor growth in the MDA-MB-231 xenograft model with minimum toxicity in animals [1]. The pharmacokinetic (PK) parameters of Xevinanapant hydrochloride were investigated in mice, rats, non-human primates, and canines [1].
|
Animal Protocol |
Animal/Disease Models: SCID (severe combined immunodeficient) mouse bearing MDA-MB-231 xenograft tumors [1]
Doses: 30 and 100 mg/kg Route of Administration: Oral; 5 days per week for 2 weeks Experimental Results: 30 and 100 mg/kg Strong Inhibits tumor growth, completely inhibiting tumor growth during treatment at 100 mg/kg. |
References |
[1]. Cai Q, Sun H, Peng Y, et al. A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J Med Chem. 2011;54(8):2714-2726.
[2]. Brunckhorst MK, et al. AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer. Cancer Biol Ther. 2012;13(9):804-811. |
Molecular Formula |
C32H44CLN5O4
|
---|---|
Molecular Weight |
597.31Elemental Analysis
|
CAS # |
1071992-57-8
|
Related CAS # |
Xevinapant;1071992-99-8
|
SMILES |
O=C([C@@H]1CC[C@@](CCN(C(CC(C)C)=O)C[C@@H]2NC([C@@H](NC)C)=O)([H])N1C2=O)NC(C3=CC=CC=C3)C4=CC=CC=C4.[H]Cl
|
InChi Key |
DBXTZCYPHKJCHF-ZZPLZQMBSA-N
|
InChi Code |
InChI=1S/C32H43N5O4.ClH/c1-21(2)19-28(38)36-18-17-25-15-16-27(37(25)32(41)26(20-36)34-30(39)22(3)33-4)31(40)35-29(23-11-7-5-8-12-23)24-13-9-6-10-14-24/h5-14,21-22,25-27,29,33H,15-20H2,1-4H3,(H,34,39)(H,35,40)1H/t22-,25+,26-,27-/m0./s1
|
Chemical Name |
(5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide hydrochloride
|
Synonyms |
AT-406 AT 406 AT406 D 1143 Debio 1143 N65WC8PXDD SM 406.
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~175 mg/mL (~292.55 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 8.75 mg/mL (14.63 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 87.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 8.75 mg/mL (14.63 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 87.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 8.75 mg/mL (14.63 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.